HIV-1 integrase inhibitors / Martin Markowitz.

Format:

Video

Author/Creator:

Markowitz, Martin, author.

Language:

English

Subjects (All):

HIV infections--Chemotherapy.

HIV infections.

Physical Description:

1 videorecording (59 min., 18 sec.) : sound, color

Place of Publication:

London : Henry Stewart Talks, 2011.

System Details:

video file

Contents:

Introduction

Talk outline

HIV integrase

Integrase function and proviral DNA integration

Strand transfer inhibitors of HIV-1 integrase

Clinically relevant HIV-1 integrase inhibitors

Raltegravir (MK-0518, Isentress)

Pivotal trials of raltegravir

Study 004 proof of concept

Protocol 004 phase Iib

Study 004: week 96 virology

Results: study 004

BENCHMRK 1 and 2, phase III

BENCHMRK 1 and 2: baseline characteristics (1)

BENCHMRK 1 and 2: baseline characteristics (2)

BENCHMRK 1 and 2: virologic response

BENCHMRK: subgroup analyses

BENCHMRK: response with additional ARVs

BENCHMRK: 96 week results

BENCHMRK: conclusions

Lessons from BENCHMRK: the TRIO study

STARTMRK study

STARTMRK: week 48 virology

STARTMRK: subgroup analyses

STARTMRK: week 48 CD4+T cell count response

STARTMRK: adverse events

STARTMRK: wk 96 lipid profiles

STARTMRK: conclusions

SWITCHMRK

SWITCHMRK1: lipids at week 12

SWITCHMRK: week 24 virology

SWITCHMRK: week 24 virology subset analysis

SWITCHMRK: conclusions

SPIRAL

SPIRAL: results - virology

SPIRAL: results - lipid profiles

SPIRAL: conclusions

Raltegravir development: future directions

Elvitegravir (GS-9137)

Elvitegravir development

Study 0101 monotherapy proof of concept trial

Study 0105

Study 0105: baseline characteristics

Study 0105: DSMB review at week 8

Study 0105: change in HIV-1 RNA levels

Study 0105: subset analyses - virology

Study 0105: conclusions

QUAD: ELV, PK enhancer and TDF/FTC

Study 236-0104: phase II QUAD

Study 236-0104: patient disposition

Study 236-0104: results week 48

Study 236-0104: clinical adverse events

Study 236-0104: effects of cobicistat on eGFR

Study 236-0104: conclusions

S/GSK-572

S/GSK 572: 10-day mono therapy

SPRING 1: study design

SPRING 1: antiviral activity

SPRING 1: conclusions

Resistance to InSTIs: general features

BENCHMRK: resistance analyses

STARTMRK: resistance results

Clonal analyses of viruses

Resistance to elvitegravir

RAL and EVG are cross resistant

In vitro passage results

572 is non cross resistant to RAL and EVG

Viking cohort 1: study design

VIKING: day 11 results

VIKING: virologic response and susceptibility

VIKING: conclusions

Talk summary and conclusions.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved April 8, 2024, from https://hstalks.com/bs/2076/.